The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Treatment sequencing in EGFR-mutated NSCLC
Mariana Brandao, MD, PhD, Jules Bordet Institute, Brussels, Belgium, shares insights into treatment sequencing for EGFR-mutated non-small cell lung cancer (NSCLC). Treatment decisions must balance quality of life with survival outcomes, and will differ depending on the patient’s priority from treatment. This is important to consider upfront during the decision for first-line treatment in order to preserve future treatment options. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
